衰弱是心脏代谢多病进展轨迹的独立风险因素:英国生物银行前瞻性研究
中位随访13.11年间,衰弱表型与各转归风险升高相关(如无CMD至单病HR 1.94,单病至CMM HR 1.63),衰弱改善可降低CMD进展与死亡风险。
要点
- 衰弱表型与无CMD至单病(HR 1.94)、无CMD至死亡(HR 2.69)风险升高相关。
- 衰弱表型与单CMD至CMM(HR 1.63)、单CMD至死亡(HR 1.67)、CMM至死亡(HR 1.57)风险升高相关。
- 衰弱指数分析结果与衰弱表型一致,衰弱改善与CMD进展及死亡风险降低相关。
核心结论
- 衰弱是CMM进展轨迹所有转归的独立风险因素。
- 针对衰弱的管理是超越实际年龄的CMM一级和二级预防的潜在策略。
研究设计与样本
- 使用多状态模型评估基线衰弱表型与衰弱指数在CMM进展轨迹中的转归特异性作用。
主要发现
- 衰弱表型相关HR:无CMD至单病1.94、无CMD至死亡2.69、单CMD至CMM 1.63、单CMD至死亡1.67、CMM至死亡1.57(均p < .001)。
- 衰弱指数分析结果与衰弱表型一致。
- 衰弱改善与CMD进展及死亡风险降低相关。
临床怎么用
- 原文结论指出衰弱是CMM进展轨迹所有转归的独立风险因素,针对衰弱的管理是超越实际年龄的CMM一级和二级预防的潜在策略。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although frailty was associated with cardiometabolic diseases (CMDs, including coronary heart disease, stroke, and diabetes here), there was no systematic analyses estimating its role in incidence, progression, and prognosis of cardiometabolic multimorbidity (CMM). METHODS: We included 351 205 participants without CMDs at baseline in UK Biobank. Occurrences of first CMD, CMM, and death were recorded. We used multistate models to assess transition-specific role of baseline frailty measured by frailty phenotype and frailty index in CMM progression trajectory from no disease to single CMD, CMM, and death. Association between changes in frailty and outcomes was investigated among 17 264 participants. RESULTS: Among 351 205 participants (44.0% male, mean age 56.55 years), 8 190 (2.3%) had frail phenotype, and 13 615 (3.9%) were moderate/severe frail according to the frailty index. During median follow-up of 13.11 years, 41 558 participants experienced ≥1 CMD, 4 952 had CMM, and 20 670 died. In multistate models, frail phenotype-related hazard ratios were 1.94 and 2.69 for transitions from no CMD to single disease and death, 1.63 and 1.67 for transitions from single CMD to CMM and death, and 1.57 for transitions from CMM to death (all p < .001). Consistent results were observed for frailty index. Improvement of frailty reduced the risk of CMD progression and death. CONCLUSIONS: Frailty is an independent risk factor for all transitions of CMM progression trajectory. Frailty-targeted management is a potential strategy for primary and secondary prevention of CMM beyond chronological age.
引用
- Ma T, He L, Luo Y, et al. Frailty, an Independent Risk Factor in Progression Trajectory of Cardiometabolic Multimorbidity: A Prospective Study of UK Biobank. J Gerontol A Biol Sci Med Sci. 2023. PMID: 37170845. doi:10.1093/gerona/glad125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。